Pharma

  • A magnifying glass enlarges the U.S. Food and Drug Administration website on a computer screen.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    5 key facts about the FDA expedited IND pilot program

    The program, part of Operation TrialBlazer, aims to speed early research and help the U.S. bring trials back from overseas.

    By Kelly Bilodeau • Oct. 7, 2026
  • Conference
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    Top pharma industry conferences in 2027

    Where pharma and biotech leaders will converge to network, share ideas and potentially strike deals.

    By • Oct. 6, 2026
  • digital pill Explore the Trendline➔
    Image attribution tooltip
    Getty Images
    Image attribution tooltip
    Trendline

    Artificial intelligence & machine learning

    After years of excited buzz around the potential of artificial intelligence and machine learning, pharma has begun to realize the true implications and potential value of these technologies.

    By PharmaVoice staff
  • Pop-art illustration showing an injectable weight-loss medication, a bathroom scale and a person’s midsection.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    The next frontier in obesity drugs: lasting weight loss

    Alveus, Lilly, Viking and Amgen are testing maintenance strategies as durability becomes a bigger focus in obesity R&D.

    By Kelly Bilodeau • Oct. 6, 2026
  • John Tsai
    Image attribution tooltip
    Permission granted by Daiichi Sankyo
    Image attribution tooltip
    Q&A

    Will there be more to Daiichi’s story than DXd ADCs?

    Dr. John Tsai grabbed the reins of global R&D this year with a clear mandate: extend Daiichi’s oncology momentum beyond its DXd franchise.

    By • Oct. 5, 2026
  • The exterior of the building housing the headquarters of Roche France, French subsidiary of the Swiss pharmaceutical group.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    Roche’s AI lab; Biohaven’s pivotal pause

    Roche announced it's building autonomous AI-powered labs; how a clinical hold on an epilepsy trial could impact Biohaven

    By PharmaVoice Staff • Oct. 2, 2026
  • Research scientist using a micropipette to mix liquid in a test tube in a laboratory.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    3 drug targets pharma is betting on next

    Companies including GSK, Merck, Roche and Sanofi are pushing new approaches in cancer and inflammatory diseases.

    By Alexandra Pecci • Oct. 2, 2026
  • Digital tablet displaying “AI AGENTS” with connected icons representing data, cloud computing and automated tools.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    An AI agent made a tiny drug R&D mistake. Then it kept going.

    The error points to a big question for pharma as AI gains autonomy and high-profile failures sharpen safety concerns: What happens when a wrong answer becomes the basis for the next decision?

    By Sy Mukherjee • Sept. 30, 2026
  • 3D-rendered network of glowing neurons firing against a dark background.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    Epilepsy R&D is breaking out of its old playbook

    Genetic medicines and more selective small molecules are finally pushing the field toward new mechanisms — and potentially disease-modifying treatments.

    By Kelly Bilodeau • Sept. 29, 2026
  • Tarja Stenvall
    Image attribution tooltip
    Permission granted by Bavarian Nordic
    Image attribution tooltip

    What Bavarian Nordic’s next CEO is up against

    The Danish biotech sharpened its global vaccine ambitions by tapping Tarja Stenvall, a Big Pharma vet, to take the helm.

    By Alexandra Pecci • Sept. 28, 2026
  • Digital illustration of a capsule containing a DNA helix and electronic circuitry against a purple and blue digital network.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    Nimbus used AI to help develop Takeda’s $4B psoriasis bet. Here’s where it’s taking the tech next

    Nimbus Therapeutics’ head of R&D dishes on what’s next in AI-enabled drug discovery, years after Takeda completed its zasocitinib acquisition.

    By Alexandra Pecci • Sept. 25, 2026
  • Wall Street buildings
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    Basecamp raises $140M before the clinic; J&J and Compass’ potential rivalry

    Some of the biggest news and trends captured in PharmaVoice’s newsletter this week. Sign up here to receive the newsletter daily. Another big AI haul Investors are still lining up to back AI drug developers before their candidates reach human trials. Basecamp Research...

    By PharmaVoice Staff • Sept. 25, 2026
  • FDA Commissioner nominee Heidi Overton testifies before Senate committee.
    Image attribution tooltip
    Tasos Katopodis via Getty Images
    Image attribution tooltip

    Where does FDA nominee Overton stand on vaccines and other key pharma issues?

    Pressed by lawmakers on Thursday, Trump’s pick as the next FDA chief said she’d “follow the law” on vaccine-related decisions and work to speed early drug R&D.

    By Jonathan Gardner • Sept. 24, 2026
  • Johnson & Johnson sign outside the company’s world headquarters.
    Image attribution tooltip
    Jeff Schear / Getty Images Entertainment via Getty Images
    Image attribution tooltip

    What J&J’s Spravato patent win could mean for psychedelic drugs

    As more psychedelic drugs move toward market, developers are testing how far patent protection can extend around familiar compounds.

    By Kelly Bilodeau • Sept. 24, 2026
  • Mike Doustdar
    Image attribution tooltip
    Permission granted by Novo Nordisk
    Image attribution tooltip

    Novo talks up drug launches in effort to win back investors

    At a “capital markets day” in London, executives outlined a roadmap to better compete with key rival Eli Lilly and soon bring forth several multibillion-dollar products. 

    By Jonathan Gardner • Sept. 23, 2026
  • Eli Lilly’s Biotechnology Center in San Diego, California, with the Lilly logo on the building.
    Image attribution tooltip
    JHVEPhoto / iStock Editorial via Getty Images
    Image attribution tooltip

    Lilly stopped showing its phase 1 pipeline. Is it playing R&D chess?

    Lilly no longer publicly lists its earliest clinical programs. The move could buy the pharma giant time to test, kill and reposition drugs while competitors are still reading the board.

    By Sy Mukherjee • Sept. 23, 2026
  • Gloved laboratory researcher holds a multiwell plate above a petri dish while using a pipette.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    CRO consolidation keeps rolling. What does that mean for pharma?

    While M&A expands one-stop shop capabilities at large CROs, pharma companies could face tradeoffs around niche expertise and service continuity.

    By Alexandra Pecci • Sept. 22, 2026
  • President Donald Trump holds up a chart comparing drug prices and Medicare Part D costs during a healthcare affordability event in the Oval Office.
    Image attribution tooltip
    Kevin Dietsch via Getty Images
    Image attribution tooltip

    A hidden tradeoff in Trump’s MFN drug deals

    The government has announced pricing agreements with 26 pharma companies. But the deals could stymie other plans to lower the country’s drug spend.

    By Kelly Bilodeau • Sept. 21, 2026
  • women's health
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    Where female participation in clinical trials has caught up — and where gaps remain

    Getting more women into drug R&D remains critical for boosting health outcomes. But in some disease areas, pharma is still falling behind.

    By Kelly Bilodeau • Sept. 16, 2026
  • Illustration of cancer cells with textured surfaces against a dark blue background.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    3 KRAS drugs to watch as the field expands

    Revolution’s pancreatic cancer approval marked a milestone in RAS-targeted treatment. Now, new treatments from Revolution, Astellas and Genentech could be the next to make a mark on the space.

    By Kelly Bilodeau • Sept. 15, 2026
  • purple filled pill capsules
    Image attribution tooltip
    Permission granted by Evonik
    Image attribution tooltip
    Sponsored by Evonik

    Making oral drug delivery more sustainable with measurable product-level data

    How auditable LCA data can guide more informed sustainability decisions.

    Sept. 14, 2026
  • A laboratory microscope sits beside test tubes as a researcher works in the background.
    Image attribution tooltip
    howtogoto via Getty Images
    Image attribution tooltip

    Cancer still dominates pharma R&D. Obesity is gaining ground.

    Oncology still accounts for nearly two out of five pipeline drugs, while obesity entered the top 10 indications and one-third of drugs target at least one rare disease.

    By Alexandra Pecci • Sept. 11, 2026
  • An all-green glass building facade with a logo that reads "MERCK" is displayed on the exterior of the research facility.
    Image attribution tooltip
    Alamy
    Image attribution tooltip

    Merck builds around Keytruda; prediction markets raise new risks

    Merck pursues new cancer combinations, prediction markets put pharma’s confidential information in focus and personalized cancer vaccines confront manufacturing hurdles.

    By PharmaVoice Staff • Sept. 11, 2026
  • A photo of Takeda president of R&D Andy Plump.
    Image attribution tooltip
    Permission granted by Takeda
    Image attribution tooltip

    Andy Plump, architect of Takeda’s R&D overhaul, to retire next year

    Plump joined Takeda during a turbulent period, pushed the company to work more closely with young biotechs and will leave it with what CEO Julie Kim called a “lasting foundation.”

    By Kristin Jensen • Sept. 10, 2026
  • A gloved scientist holds a blood sample in front of a monitor displaying a brain MRI scan.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    5 questions that could determine Alzheimer’s next chapter

    “The Alzheimer’s space has really got a fire under it,” says one analyst. But can the momentum deliver better drugs?

    By Kelly Bilodeau • Sept. 9, 2026
  • Illustration of an antibody-drug conjugate with a blue and purple antibody linked to an orange cytotoxic payload.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    Merck pairs ADCs with Keytruda in women’s cancer push

    The drugmaker hopes to move the needle on challenging cancers and shore up its pipeline as it prepares for the Keytruda patent cliff.

    By Kelly Bilodeau • Sept. 9, 2026